Editas Medicine Overview
Editas Medicine Target Price
Analysts' 12-month price predictions for EDIT.
Get informed when a big investor buys or sells
+ FollowShare Price
$3.65
Average Target Price
$5.00
37% upside
37% upside2 analysts in the last 4 months
High: $6 | Low: $4
Analyst Recommendations
No recommendations in the last 4 months.
Revenue & Income Forecast
Analysts' Target Prices
| Date | Analyst | Price Target | Current Upside/Downside | |
|---|---|---|---|---|
| 2026-05-05 | Chardan Capital | $4 | 9.6% upside |  |
| 2026-03-09 | Robert W. Baird | $6 | 64.4% upside | |
| 2024-11-05 | BarclaysGena Wang | $5 | 37% upside | |
| 2024-10-23 | Wells FargoYanan Zhu | $9 | 146.6% upside | |
| 2024-10-22 | Robert W. BairdJoel Beatty | $10 | 174% upside | |
| 2024-08-08 | Truist FinancialJoon Lee | $12 | 228.8% upside | |
| 2024-08-08 | Bank of America SecuritiesGreg Harrison | $15 | 311% upside | |
| 2024-05-30 | Evercore ISILiisa Bayko | $7 | 91.8% upside | |
| 2024-05-09 | Morgan StanleyMatthew Harrison | $7 | 91.8% upside | |
| 2023-09-28 | Stifel NicolausDae Gon Ha | $17 | 365.8% upside | |
| 2022-12-13 | Citigroup | $11 | 201.4% upside | |
| 2022-11-18 | Morgan Stanley | $8 | 119.2% upside | |
| 2022-11-18 | RBC Capital | $14 | 283.6% upside | |
| 2022-11-18 | Truist FinancialJoon Lee | $35 | 858.9% upside | |
| 2022-11-18 | Oppenheimer | $12 | 228.8% upside | |
| 2022-11-18 | Credit Suisse | $13 | 256.2% upside | |
| 2022-11-18 | Chardan Capital | $35 | 858.9% upside | |
| 2022-01-06 | Morgan StanleyMatthew Harrison | $24 | 557.5% upside | |
| 2021-11-08 | Robert W. BairdJoel Beatty | $44 | 1105.5% upside | |
| 2021-09-29 | Truist FinancialJoon Lee | $80 | 2091.8% upside | |